Choroidal Neovascularization - 17 Studies Found Recruiting : AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) : Macular Degeneration, Choroidal Neovascularization : 2015-06-12 : Drug: RG7716 Participants will Completed : Efficacy/Safety of Verteporfin Photodynamic Therapy and Ranibizumab Compared With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization : Macular Degeneration Choroidal Neovascularization : 2007-02-16 : Drug: Verteporfin Photodynamic Therapy Completed : A Study of the Criteria Establishing the Need for Re-treatment With Ranibizumab Upon Relapse in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia. : Choroidal Neovascularization Secondary to Pathologic Myopia : 2014-01-09 : Drug: Ranibizumab All patients will receive a single initial intravitreal injection of ranibizumab 0.5 m Completed : Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration : Choroidal Neovascularization Macular Degeneration : 1999-11-03 : Drug: Corticosteroid Completed : An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO : Choroidal Neovascularization, Age-related Macular Degeneration : 2006-09-21 : Drug: Ranibizumab 0.5 mg Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an Terminated : Verteporfin Photodynamic Therapy Administered in Conjunction With Ranibizumab in Patients With Subfoveal Choroidal Neovascularization Secondary to Age-related Macular Degeneration (AMD) : Macular Degeneration Choroidal Neovascularization : 2007-02-08 : Drug: Verteporfin Photodynamic Therapy Recruiting : Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients : Idiopathic Choroidal Neovascularization : 2014-10-02 : Drug: aflibercept The patients are followed on a monthly basis until 52 weeks. Intravitreal injections o <<< Previous
